We are live on
!
Find out more
CP
Caligan Partners Portfolio holdings
AUM
$1.5B
1-Year Est. Return
518.95%
This Fund
S&P 500
This Quarter
Est. Return
+1.33%
1 Year Est. Return
+518.95%
3 Year Est. Return
+1,728.44%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$218M
AUM Growth
+$39.9M
(+22%)
Cap. Flow
+$42.2M
Cap. Flow
% of AUM
19.4%
Top 10 Holdings %
Top 10 Hldgs %
99.52%
Holding
15
New
2
Increased
3
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALIM
Alimera Sciences
ALIM
|
+$54.1M |
| 2 |
Anika Therapeutics
ANIK
|
+$7.49M |
| 3 |
Verrica Pharmaceuticals
VRCA
|
+$1.32M |
| 4 |
SCTL
Societal CDMO, Inc. Common Stock
SCTL
|
+$437K |
| 5 |
YMAB
Y-mAbs Therapeutics
YMAB
|
+$136K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$14.6M |
| 2 |
EyePoint Inc
EYPT
|
+$2.7M |
| 3 |
Standard BioTools
LAB
|
+$2.21M |
| 4 |
ADMA Biologics
ADMA
|
+$962K |
| 5 |
Evolus
EOLS
|
+$684K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Liquidia Corp
LQDA
$7.72B
| $58.6M | 26.91% |
9,243,627
| – | – |
|
|
ALIM
2
DELISTED
Alimera Sciences
ALIM
| $52.2M | 23.97% |
16,835,154
+16,356,377
| +3,416% | +$54.1M |
|
|
ICPT
3
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $22.2M | 10.22% |
1,200,000
| – | – |
|
|
4
Standard BioTools
LAB
$311M
| $22.1M | 10.15% |
7,622,413
-845,507
| -10% | -$2.21M |
|
|
5
Anika Therapeutics
ANIK
$202M
| $20.1M | 9.25% |
1,081,360
+361,069
| +50% | +$7.49M |
|
6
Exelixis
EXEL
$14.2B
| $19.9M | 9.14% |
910,730
| – | – |
|
|
7
Evolus
EOLS
$410M
| $15.4M | 7.07% |
1,683,836
-76,300
| -4% | -$684K |
|
|
VRNA
8
DELISTED
Verona Pharma
VRNA
| $2.98M | 1.37% |
183,064
| – | – |
|
|
9
ADMA Biologics
ADMA
$2.04B
| $2.14M | 0.98% |
597,513
-250,000
| -29% | -$962K |
|
|
10
Verrica Pharmaceuticals
VRCA
$92.8M
| $1.01M | 0.46% |
+25,959
| New | +$1.32M |
|
|
SCTL
11
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $794K | 0.36% |
1,689,768
+612,500
| +57% | +$437K |
|
|
YMAB
12
DELISTED
Y-mAbs Therapeutics
YMAB
| $127K | 0.06% |
+23,321
| New | +$136K |
|
13
Agios Pharmaceuticals
AGIO
$2.14B
| $120K | 0.05% |
4,833
| – | – |
|
|
14
EyePoint Inc
EYPT
$1B
| – | – |
-310,298
| Closed | -$2.7M |
|
|
ICPT
15
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – |
-1,293,510
| Closed | -$14.6M |
|
Similar funds
BFO
JFGLC
AAM
TP
SCM
NSGL
FMI
RCW
Caligan Partners's Q3 2023 Portfolio in Review
As of Q3 2023, Caligan Partners held 15 positions worth $218M, up 22% from $178M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Caligan Partners deployed $42.2M of net new capital in Q3 2023, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was Verrica Pharmaceuticals: 25,959 shares worth $1.01M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 93% a quarter earlier.
On the sell side, the largest reduction was Standard BioTools, an estimated $2.21M trimmed.
- Caligan Partners's largest Q3 2023 buy was Verrica Pharmaceuticals: 25,959 shares worth $1.01M.
- Caligan Partners added most to Alimera Sciences in Q3 2023, an estimated $54.1M increase.
- Caligan Partners's biggest Q3 2023 reduction was Standard BioTools, cutting an estimated $2.21M.
- Caligan Partners fully exited Intercept Pharmaceuticals, Inc. in Q3 2023, selling an estimated $14.6M.
- Caligan Partners's ten largest holdings make up 100% of its $218M portfolio in Q3 2023.
- Caligan Partners opened 2 new positions and closed 2 in Q3 2023.
- Caligan Partners's portfolio value rose 22% quarter-over-quarter to $218M.
Based on Caligan Partners's 13F filing for Q3 2023, filed 14 Nov 2023.